Article
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.
Breast cancer research and treatment - 1 Apr 2012
Marmé Frederik, Werft Wiebke, Walter Anne, Keller Sascha, Wang Xiaoli, Benner Axel, Burwinkel Barbara, Sinn Peter, Hug Sarah, Sohn Christof, Bretz Niko, Moldenhauer Gerhard, Rupp Christian, Rupp Anne-Kathleen, Biakhov Mikhail Y, Bottini Alberto, Friedrichs Kay, Khailenko V A, Manikhas Georgiy M, Ruiz Amparo, Sánchez-Rovira Pedro, Santoro Armando, Segui Miguel A, Villena Carlos, Lichter Peter, Kristiansen Glen, Altevogt Peter, Schneeweiss Andreas
Abstract excerpt
Overexpression of CD24 is an independent prognostic factor for breast cancer. Recently, two polymorphisms in the CD24 gene were linked to disease risk and progression in autoimmune diseases. Here, we evaluated the clinical relevance of these polymorphisms with respect to their potential to predict a pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) for primary breast cancer (PBC), one of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.